journal article·2020-07-28Open access

Nanotechnology for COVID-19: Therapeutics and Vaccine Research

Gaurav Chauhan, Marc J. Madou, Sourav Kalra, Vianni Chopra, Deepa Ghosh, Sergio O. Martinez-Chapa

ACS Nano· Volume 14· Issue 7

Abstract

The current global health threat by the novel coronavirus disease 2019 (COVID-19) requires an urgent deployment of advanced therapeutic options available. The role of nanotechnology is highly relevant to counter this "virus" nano enemy. Nano intervention is discussed in terms of designing effective nanocarriers to counter the conventional limitations of antiviral and biological therapeutics. This strategy directs the safe and effective delivery of available therapeutic options using engineered nanocarriers, blocking the initial interactions of viral spike glycoprotein with host cell surface receptors, and disruption of virion construction. Controlling and eliminating the spread and reoccurrence of this pandemic demands a safe and effective vaccine strategy. Nanocarriers have potential to design risk-free and effective immunization strategies for severe acute respiratory syndrome coronavirus 2 vaccine candidates such as protein constructs and nucleic acids. We discuss recent as well as ongoing nanotechnology-based therapeutic and prophylactic strategies to fight against this pandemic, outlining the key areas for nanoscientists to step in.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: SARS-CoV-2 and COVID-19 Research · Immunotherapy and Immune Responses · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Engineering and Sciences, Tecnologico de Monterrey, Av. Eugenio Garza Sada 2501 Sur, 64849 Monterrey, Nuevo León, Mexico

Department of Mechanical and Aerospace Engineering, University of California Irvine, Engineering Gateway 4200, Irvine, California 92697, United States

Department of Pharmaceutical Technology (Process Chemistry), National Institute of Pharmaceutical Education and Research, Sector 67, S.A.S. Nagar, Punjab 160062, India

Institute of Nano Science and Technology, Habitat Centre, Phase 10 Mohali, 160062 Punjab, India

Funding

Consejo Nacional de Ciencia y Tecnolog??a · Federico Baur Endowed Chair in Nanotechnology

References (100+)

Show source-provided references
1. 10.1038/s41579-020-0332-010.1038/s41579-020-0332-0 ↗
2. 10.1016/j.ijid.2020.03.00410.1016/j.ijid.2020.03.004 ↗
3. Coronavirus Disease 2019 (COVID-19) Situation Report-68. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200328-sitrep-68-covid-19.pdf?sfvrsn=384bc74c_2 (accessed 2020-04-11).
4. 10.1038/d41586-020-00551-110.1038/d41586-020-00551-1 ↗
5. 10.23750/abm.v91i1.939710.23750/abm.v91i1.9397 ↗
6. 10.1136/bmj.m125110.1136/bmj.m1251 ↗
7. 10.1093/jtm/taaa03710.1093/jtm/taaa037 ↗
8. Econ. Outlook · 2020 · 44 · 110.1111/1468-0319.12508 ↗
9. 10.2139/ssrn.354772910.2139/ssrn.3547729 ↗
10. 10.1038/s41586-020-2012-710.1038/s41586-020-2012-7 ↗
11. 10.3390/v1101005910.3390/v11010059 ↗
12. 10.1038/s41579-018-0118-910.1038/s41579-018-0118-9 ↗
13. 10.1038/s41569-020-0360-510.1038/s41569-020-0360-5 ↗
14. 10.1016/S2468-1253(20)30084-410.1016/S2468-1253(20)30084-4 ↗
15. 10.1016/S2468-1253(20)30057-110.1016/S2468-1253(20)30057-1 ↗
16. 10.1161/01.HYP.0000185148.27901.fe10.1161/01.HYP.0000185148.27901.fe ↗
17. 10.1016/j.kint.2020.03.00510.1016/j.kint.2020.03.005 ↗
18. 10.1111/jgh.1504710.1111/jgh.15047 ↗
19. 10.1016/j.jaut.2020.10243310.1016/j.jaut.2020.102433 ↗
20. 10.1016/S0140-6736(20)30374-310.1016/S0140-6736(20)30374-3 ↗
21. 10.1016/S0065-3527(06)66005-310.1016/S0065-3527(06)66005-3 ↗
22. 10.1016/j.antiviral.2014.06.01310.1016/j.antiviral.2014.06.013 ↗
23. 10.1016/j.febslet.2004.09.00910.1016/j.febslet.2004.09.009 ↗
24. 10.18632/oncotarget.847510.18632/oncotarget.8475 ↗
25. 10.1016/S0065-3527(05)64006-710.1016/S0065-3527(05)64006-7 ↗
26. Tooze J. · Eur. J. Cell Biol. · 1984 · 33 · 281
27. 10.1016/j.jsb.2010.11.02110.1016/j.jsb.2010.11.021 ↗
28. 10.1128/JVI.05300-1110.1128/JVI.05300-11 ↗
29. 10.1128/mBio.00473-1210.1128/mBio.00473-12 ↗
30. 10.1038/nrmicro214710.1038/nrmicro2147 ↗
31. 10.1016/j.cell.2020.04.01110.1016/j.cell.2020.04.011 ↗
32. 10.1038/s41586-020-2179-y10.1038/s41586-020-2179-y ↗
33. 10.1006/viro.2000.075710.1006/viro.2000.0757 ↗
34. 10.1016/j.antiviral.2013.09.02810.1016/j.antiviral.2013.09.028 ↗
35. 10.1073/pnas.080952410610.1073/pnas.0809524106 ↗
36. 10.1073/pnas.030644610110.1073/pnas.0306446101 ↗
37. 10.1371/journal.ppat.100723610.1371/journal.ppat.1007236 ↗
38. 10.1126/science.111648010.1126/science.1116480 ↗
39. 10.1126/science.abb250710.1126/science.abb2507 ↗
40. 10.1016/j.virusres.2014.11.02110.1016/j.virusres.2014.11.021 ↗
41. 10.1073/pnas.050557710210.1073/pnas.0505577102 ↗
42. 10.1126/science.abb276210.1126/science.abb2762 ↗
43. 10.1038/s41586-020-2180-510.1038/s41586-020-2180-5 ↗
44. 10.1128/JVI.00127-2010.1128/JVI.00127-20 ↗
45. 10.1016/j.cell.2020.02.05810.1016/j.cell.2020.02.058 ↗
46. 10.1080/22221751.2020.172906910.1080/22221751.2020.1729069 ↗
47. Liu, C.; Yang, Y.; Gao, Y.; Shen, C.; Ju, B.; Liu, C.; Tang, X.; Wei, J.; Ma, X.; Liu, W. Viral Architecture of SARS-CoV-2 with Post-Fusion Spike Revealed by Cryo-EM. bioRxiv, March 5, 2020. https://www.biorxiv.org/content/10.1101/2020.03.02.972927v1 (accessed 2020-04-24).10.1101/2020.03.02.972927 ↗
48. 10.1016/S0140-6736(20)30251-810.1016/S0140-6736(20)30251-8 ↗
49. 10.1038/s41586-020-2008-310.1038/s41586-020-2008-3 ↗
50. 10.6026/9732063001621910.6026/97320630016219 ↗
51. 10.1016/S0140-6736(20)30183-510.1016/S0140-6736(20)30183-5 ↗
52. 10.1016/S2213-2600(20)30076-X10.1016/S2213-2600(20)30076-X ↗
53. 10.1002/jmv.2568510.1002/jmv.25685 ↗
54. 10.1038/nrmicro.2016.8110.1038/nrmicro.2016.81 ↗
55. 10.1084/jem.2005082810.1084/jem.20050828 ↗
56. 10.1007/s12250-020-00207-410.1007/s12250-020-00207-4 ↗
57. 10.1172/jci.insight.12315810.1172/jci.insight.123158 ↗
58. 10.1002/rmv.210710.1002/rmv.2107 ↗
59. 10.1056/NEJMoa200203210.1056/NEJMoa2002032 ↗
60. 10.1136/bmj.326.7403.135810.1136/bmj.326.7403.1358 ↗
61. 10.1038/s41577-020-0311-810.1038/s41577-020-0311-8 ↗
62. 10.1016/j.ijid.2020.03.05310.1016/j.ijid.2020.03.053 ↗
63. 10.1074/jbc.M00261520010.1074/jbc.M002615200 ↗
64. 10.1002/path.157010.1002/path.1570 ↗
65. 10.1016/j.tips.2004.04.00110.1016/j.tips.2004.04.001 ↗
66. 10.1016/S1050-1738(02)00233-510.1016/S1050-1738(02)00233-5 ↗
67. 10.1128/JVI.02560-0910.1128/JVI.02560-09 ↗
68. 10.1016/j.carpath.2020.10722810.1016/j.carpath.2020.107228 ↗
69. 10.3390/v1201001410.3390/v12010014 ↗
70. 10.1186/s40779-020-00240-010.1186/s40779-020-00240-0 ↗
71. 10.1016/S0022-510X(02)00207-110.1016/S0022-510X(02)00207-1 ↗
72. 10.1021/acschemneuro.0c0020110.1021/acschemneuro.0c00201 ↗
73. 10.1053/j.gastro.2020.02.05510.1053/j.gastro.2020.02.055 ↗
74. 10.1152/ajpregu.90592.200810.1152/ajpregu.90592.2008 ↗
75. 10.1371/journal.pone.023029510.1371/journal.pone.0230295 ↗
76. Tang, B.; He, F.; Liu, D.; Fang, M.; Wu, Z.; Xu, D. AI-Aided Design of Novel Targeted Covalent Inhibitors against SARS-CoV-2. bioRxiv, March 8, 2020. https://www.biorxiv.org/content/10.1101/2020.03.03.972133v1 (accessed 2020-04-07).10.1101/2020.03.03.972133 ↗
77. 10.1038/s41421-020-0153-310.1038/s41421-020-0153-3 ↗
78. 10.1021/acs.jmedchem.9b0191310.1021/acs.jmedchem.9b01913 ↗
79. 10.5582/ddt.2020.0101210.5582/ddt.2020.01012 ↗
80. Weston, S.; Haupt, R.; Logue, J.; Matthews, K.; Frieman, M. FDA Approved Drugs with Broad Anti-Coronaviral Activity Inhibit SARS-CoV-2 In Vitro. bioRxiv, March 27, 2020. https://www.biorxiv.org/content/10.1101/2020.01.31.929695v2 (accessed 2020-04-07).
81. 10.1016/j.apsb.2020.02.00810.1016/j.apsb.2020.02.008 ↗
82. 10.1038/s41586-020-2286-910.1038/s41586-020-2286-9 ↗
83. 10.1126/science.abb340510.1126/science.abb3405 ↗
84. Lin, S.; Shen, R.; He, J.; Li, X.; Guo, X. Molecular Modeling Evaluation of the Binding Effect of Ritonavir, Lopinavir and Darunavir to Severe Acute Respiratory Syndrome Coronavirus 2 Proteases. bioRxiv, February 18, 2020. https://www.biorxiv.org/content/10.1101/2020.01.31.929695v2 (accessed 2020-04-07).10.1101/2020.01.31.929695 ↗
85. 10.1016/j.antiviral.2014.12.01510.1016/j.antiviral.2014.12.015 ↗
86. 10.1128/JVI.01815-1810.1128/JVI.01815-18 ↗
87. 10.1016/j.cell.2020.02.05210.1016/j.cell.2020.02.052 ↗
88. 10.1002/jmv.2576110.1002/jmv.25761 ↗
89. 10.1038/nrmicro209010.1038/nrmicro2090 ↗
90. DrugBank. https://www.drugbank.ca/drugs (accessed 2020-04-25).
91. 10.1021/ci000392t10.1021/ci000392t ↗
92. 10.1021/ci025515j10.1021/ci025515j ↗
93. 10.1021/ci010368v10.1021/ci010368v ↗
94. 10.4014/jmb.1812.1202410.4014/jmb.1812.12024 ↗
95. 10.1371/journal.ppat.100471710.1371/journal.ppat.1004717 ↗
96. 10.1073/pnas.070100010410.1073/pnas.0701000104 ↗
97. 10.1016/j.it.2020.03.00710.1016/j.it.2020.03.007 ↗
98. 10.1016/j.medidd.2020.10001910.1016/j.medidd.2020.100019 ↗
99. 10.1371/journal.pone.005036610.1371/journal.pone.0050366 ↗
100. 10.1016/j.cell.2018.12.02810.1016/j.cell.2018.12.028 ↗